LINC02210-CRHR1

Across TCGA pan-cancer cohorts, LINC02210-CRHR1 RNA differs between tumor and matched normal tissue in 3 of 18 cancer types tested, making tumor–normal expression one of LINC02210-CRHR1’s most consistent transcriptional readouts.

The strongest signal is observed in thyroid carcinoma (THCA), where LINC02210-CRHR1 RNA is repressed in tumor relative to normal tissue. In most cancer types LINC02210-CRHR1 is over-expressed in tumor, although a few such as THCA show the opposite, repressed pattern.

THCA, BLCA, and LUAD are the cancer types where LINC02210-CRHR1 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in LINC02210-CRHR1 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
THCA	All	IV	−0.140	.001	7	view →
BLCA	All	III,IV	+0.040	.047	1	view →
LUAD	Female	All	+0.028	.036	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 3 strongest of 3 lineages.

LINC02210-CRHR1–THCA

Open the THCA breakdown →